Dermata Therapeutics, Inc. financial data

Symbol
DRMA, DRMAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
3525 Del Mar Heights Rd., #322, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 18.7 % +16.7%
Return On Equity -141 % -21.7%
Return On Assets -119 % -19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.66 M shares +185%
Common Stock, Shares, Outstanding 6.66 M shares +179%
Entity Public Float 4.8 M USD +20%
Common Stock, Value, Issued 666 USD +179%
Weighted Average Number of Shares Outstanding, Basic 8.35 M shares +337%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.48 M USD -14.7%
General and Administrative Expense 4.49 M USD +14.6%
Operating Income (Loss) -8.97 M USD +2.16%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -8.69 M USD +4.15%
Earnings Per Share, Basic -2.67 USD/shares +80.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.63 M USD -17.8%
Assets 5.18 M USD -44.3%
Accounts Payable, Current 823 K USD +66.9%
Liabilities 1.37 M USD +13.6%
Retained Earnings (Accumulated Deficit) -56.5 M USD -18.2%
Stockholders' Equity Attributable to Parent 3.81 M USD -52.9%
Liabilities and Equity 5.18 M USD -44.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.7 M USD -63.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 250 M shares 0%
Common Stock, Shares, Issued 6.66 M shares +179%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.73 M USD -46%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 5.46 M USD +47.3%
Deferred Tax Assets, Gross 5.46 M USD +47.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 2.98 M USD +54.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 645 K USD +15.8%
Additional Paid in Capital 60.3 M USD +7.88%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 235 K USD +64.7%
Interest Expense 655 USD -100%